AIM Immunotech Inc. Form 8-K Summary
Business Context and Reporting Period
Company: AIM Immunotech Inc.
Filing Date: May 7, 2026
Reporting Period: Current Report (Event Date: May 7, 2026)
Principal Office: Ocala, FL
Exchange: NYSE American (Symbol: AIM)
The Company entered into a warrant exercise inducement offer letter agreement to facilitate the exercise of existing warrants by holders in exchange for new warrants with more favorable terms.
Key Financial Metrics and Transaction Details
Transaction Overview: Warrant Exercise Inducement (Warrant Inducement)
- Existing Warrants Involved:
- Class A & B (May 2024): 112,819 shares @ $36.30 exercise price.
- Class C & D (Sept 2024): 93,061 shares @ $28.00 exercise price.
- Class E & F (July 2025): 8,514,048 shares @ $1.439 exercise price.
- Reduced Exercise Price: $0.48 per share for all Existing Warrants.
- Inducement Warrants (New):
- Class H warrants issued equal to 200% of shares issued upon exercise of Existing Warrants.
- Total Inducement Warrant Shares: Up to 17,439,856 shares.
- Exercise Price: $0.60 per share.
- Term: 5 years from the Stockholder Approval Date.
- Projected Gross Proceeds: Approximately $4.20 million (if all Existing Warrants are exercised).
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Agreements
Placement Agent Agreement:
- Agent: Ladenburg Thalmann & Co. Inc.
- Cash Fee: 8.0% of aggregate gross proceeds.
- Expense Reimbursement: Up to $50,000.
- Management Fee: 0.75% of aggregate gross proceeds.
- Placement Agent Warrants: Warrants to purchase up to 6% of the shares issued to Holders.
- Exercise Price: 125% of the Reduced Exercise Price ($0.60).
- Term: 5 years from issuance.
Regulatory and Closing Conditions:
- Stockholder Approval: Required for the issuance of Inducement Warrant Shares under NYSE American rules. A meeting must be convened within 75 days of closing.
- Closing Date: Expected May 8, 2026.
- Registration: Company to file Form S-3 within 30 days of Closing to register resale of Inducement Warrant Shares.
Guidance, Risks, and Contingencies
- Contingency: The issuance of Inducement Warrant Shares is contingent upon stockholder approval. If approval is not obtained, the transaction terms regarding the new warrants may not be finalized.
- Unregistered Securities: Inducement Warrants were issued under Section 4(a)(2) exemption and are not registered under the Securities Act of 1933.
- Dilution Risk: The transaction significantly increases the potential share count through the issuance of 200% new warrants relative to the exercised shares.
- Financial Impact: The filing does not provide current revenue, profit, or cash flow data; it focuses solely on the capital raise mechanics.
Investor Verification Checklist
- Verify the outcome of the stockholder vote required for the issuance of Inducement Warrant Shares.
- Confirm the actual number of Existing Warrants exercised versus the maximum potential (8,719,928 shares).
- Monitor the filing and effectiveness of the Form S-3 registration statement for the Inducement Warrant Shares.
- Review the final closing date and actual gross proceeds received compared to the $4.20 million projection.
- Assess the impact of the 17,439,856 new warrant shares on future dilution and earnings per share.